EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Dec 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-12-22

Reporting Person: Ross Leonard S (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-22	Common Stock	M	62892	—	Acquired	94709	Direct
2018-12-22	Common Stock	F	18522	$1.65	Disposed	76187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-22	Restricted stock units	$	M	62892	Disposed		Common Stock (62892)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

F3: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on December 21, 2018.

F4: On December 22, 2017, the reporting person was granted 62,892 restricted stock units, vesting in full on the first anniversary of the grant date.